Thiazolidinediones or glitazones (TZDs) represent established drugs that treat insulin resistance in type 2 diabetes mellitus [1,2], which is a chronic metabolic disorder caused by defects in insulin secretion and insulin action [3]. This evidence concerns the gene INS and Insulin resistance.